阿勒替尼、enterrectinib或Vemurafenib + Cobimetinib治疗伴有ALK、ROS1、NTRK或BRAF v600E分子改变的I-III期非小细胞肺癌患者的研究

{"title":"阿勒替尼、enterrectinib或Vemurafenib + Cobimetinib治疗伴有ALK、ROS1、NTRK或BRAF v600E分子改变的I-III期非小细胞肺癌患者的研究","authors":"","doi":"10.31525/ct1-nct04302025","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":9602,"journal":{"name":"Case Medical Research","volume":"11 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Study of Alectinib, Entrectinib, or Vemurafenib Plus Cobimetinib in Participants With Stages I-III Non-Small Cell Lung Cancer With ALK, ROS1, NTRK, or BRAF v600E Molecular Alterations\",\"authors\":\"\",\"doi\":\"10.31525/ct1-nct04302025\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":9602,\"journal\":{\"name\":\"Case Medical Research\",\"volume\":\"11 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-03-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Case Medical Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.31525/ct1-nct04302025\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Medical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31525/ct1-nct04302025","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}